Orthocell (ASX:OCC) said it sold 100 units of its Remplir nerve repair product in the US, according to a Thursday Australian bourse filing.
This follows 61 active submissions to US hospital Value Analysis Committees, with 17 approvals secured ahead of schedule and additional approvals anticipated in fiscal 2026, the filing said. The first 4,000 units of Remplir have been shipped from Australia and warehoused in the US.
Orthocell's shares fell past 2% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.